Association of tumor burden with outcome in first-line therapy with nivolumab plus ipilimumab for previously untreated metastatic renal cell carcinoma.

导出原文传递

翻译打印收藏纠错

第一作者： Hiroki,Ishihara

第一单位： Department of Urology, Tokyo Women's Medical University Medical Center East, Tokyo, Japan.

作者： Hiroki,Ishihara ^[1] ; Tsunenori,Kondo ^[1] ; Kazutaka,Nakamura ^[2] ; Yuki,Nemoto ^[3] ; Hidekazu,Tachibana ^[4] ; Hironori,Fukuda ^[5] ; Kazuhiko,Yoshida ^[5] ; Hirohito,Kobayashi ^[1] ; Junpei,Iizuka ^[5] ; Hiroaki,Shimmura ^[2] ; Yasunobu,Hashimoto ^[3] ; Kazunari,Tanabe ^[5] ; Toshio,Takagi ^[5]

作者单位： Department of Urology, Tokyo Women's Medical University Medical Center East, Tokyo, Japan. ^[1] Department of Urology, Tokiwakai Jyoban Hospital, Fukushima, Japan. ^[2] Department of Urology, Saiseikai Kawaguchi General Hospital, Saitama, Japan. ^[3] Department of Urology, Tokyo Women's Medical University Medical Center East, Tokyo, Japan.;Department of Urology, Saiseikai Kurihashi Hospital, Saitama, Japan. ^[4] Department of Urology, Tokyo Women's Medical University, Tokyo, Japan. ^[5]

关键词 CTLA-4 PD-1 RCC advanced renal cell carcinoma immunotherapy

主题词抗肿瘤联合化疗方案(Antineoplastic Combined Chemotherapy Protocols);癌, 肾细胞(Carcinoma, Renal Cell);人类(Humans);肾肿瘤(Kidney Neoplasms);回顾性研究(Retrospective Studies);肿瘤负荷(Tumor Burden)

DOI 10.1093/jjco/hyab142

PMID 34492101

发布时间 2021-12-14

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交